Mirxes Launches Up to HK$1.1 Billion Hong Kong IPO
Mirxes has launched its initial public offering (IPO) in Hong Kong, aiming to raise up to HK$1.09 billion by offering 46,620,000 shares at HK$23.30 each. The company plans to use the funds for R&D of its cancer screening product GASTROClear, integration of capabilities, and working capital. Allocation results will be disclosed on May 22, with trading starting on May 23. Beijing Xunrui and Evergreen Gate are cornerstone investors, while several firms are acting as joint bookrunners and lead managers for the IPO.
Mirxes (HKG:2629) launched its initial public offering in Hong Kong Thursday, seeking to raise up to HK$1.09 billion from the deal.
The Singapore-headquartered micro ribonucleic acid technology company is offering up to 46,620,000 at HK$23.30 per share, according to a Thursday filing with the Hong Kong Stock Exchange.
Mirxes will disclose allocation results on May 22. Shares will begin trading on the stock exchange on May 23.
The micro RNA technology company intends to use the proceeds for research and development for its core cancer screening product GASTROClear and its pipeline products, integration of its end-to-end capabilities, and for working capital.
Mirxes attracted Beijing Xunrui and Evergreen Gate as cornerstone investor.
China International Capital Corp. Hong Kong Securities, CCB International Capital, CMBC Securities, CMB International Capital, Soochow Securities International, Livermore Holdings, BOCOM International Securities, and Platinum Broking, are the joint bookrunners and lead managers of the IPO.
Waton Securities International, Alpha Win Capital, Imperium International Securities, Kingkey Securities Group, and Yuen Meta (International), are also joint lead managers of the offering.
